Microba Appoints Therapeutics Head
April 05 2022 - 9:04PM
Business Wire
- Appointment of Professor Trent Munro as Senior Vice
President of Therapeutics.
- Professor Munro has over 25 years’ research and development
experience, including with multinational biopharmaceutical company
Amgen based in California, United States.
- Professor Munro has recently held several leadership roles
in Australia including Director of the National Biologics Facility
(NBF), Program Director of the CEPI funded Rapid Response Vaccine
pipeline and Director of the ARC Centre for Biopharmaceutical
Innovation (CBI).
Microba Life Sciences Limited (ASX: MAP) (“Microba” or
the “Company”) is pleased to announce Professor Trent Munro will be
joining the company as Senior Vice President of Therapeutics.
Professor Munro has over 25 years’ research and development
experience, including with multinational biopharmaceutical company
Amgen.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20220405006299/en/
Professor Trent Munro, Senior Vice
President of Therapeutics, Microba Life Sciences (Photo: Business
Wire)
Commenting on the appointment, Chief Executive Officer Dr Luke
Reid said, “As the company enters into clinical trials, Professor
Munro brings significant pharmaceutical and US drug development
experience to advance our therapeutic programs and establish
partnerships with large pharmaceutical companies.”
Professor Trent Munro commences employment with Microba today,
Wednesday, April 6, and will be leading the Company’s therapeutic
strategy to progress its valuable drug development programs and
pharma partnering engagements.
About Prof Trent Munro
Professor Munro was based in California with Amgen for over six
years, including in the role of Executive Director leading a global
team. During this time, he played key roles in the translation of
molecules from research, through clinical trials, regulatory
approval, and global licensure. This included a diverse range of
programs spanning novel biologics, small molecules, nucleic
acid-based, cell-based and gene-based therapies across multiple
therapeutic areas.
In the last two years Professor Munro has held several
leadership roles in Australia including Director of the National
Biologics Facility (NBF), Program Director of the CEPI funded Rapid
Response Vaccine pipeline, Director of the ARC Centre for
Biopharmaceutical Innovation (CBI) and Senior Group Leader at the
Australian Institute for Bioengineering and Nanotechnology (AIBN)
at the University of Queensland.
Professor Munro completed postdoctoral studies in cell biology
and developmental genetics at Harvard Medical School and the
University of Cambridge and has a PhD in Protein Biochemistry from
the University of Queensland.
This announcement has been authorised for release by the
Board.
About Microba Life Sciences Limited
Microba Life Sciences is a precision microbiome company driven
to improve human health. With world-leading technology for
measuring the human gut microbiome, Microba is driving the
discovery and development of novel therapeutics for major chronic
diseases and delivering gut microbiome testing services globally to
researchers, clinicians, and consumers. Through partnerships with
leading organisations, Microba is powering the discovery of new
relationships between the microbiome, health and disease for the
development of new health solutions.
For more information visit: www.microba.com
Microba encourages all current investors to go paperless by
registering their details with the designated registry service
provider, Automic Group.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220405006299/en/
Dr Luke Reid Chief Executive Officer Luke.Reid@microba.com
Simon Hinsley Investor / Media Relations
simon@nwrcommunications.com.au +61 401 809 653
Microba Life Sciences (ASX:MAP)
Historical Stock Chart
From Jul 2024 to Aug 2024
Microba Life Sciences (ASX:MAP)
Historical Stock Chart
From Aug 2023 to Aug 2024